John Ruesch

Corporate Officer/Principal presso ASTRIA THERAPEUTICS, INC.

Health Technology

Consumer Services

Profilo

John Ruesch is currently the Senior Vice President-Pharmaceutical Sciences at Astria Therapeutics, Inc. Prior to this, he worked as the Vice President-Pharmaceutical Development at Surface Oncology, Inc. Mr. Ruesch completed his undergraduate degree at Valparaiso University and earned an MBA from Kellogg School of Management.

Posizioni attive di John Ruesch

Società	Posizione	Inizio
ASTRIA THERAPEUTICS, INC.	Corporate Officer/Principal	17/07/2023

Tutte le posizioni attive di John Ruesch

Precedenti posizioni note di John Ruesch

Società	Posizione	Fine
SURFACE ONCOLOGY, INC.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di John Ruesch

Formazione di John Ruesch

Valparaiso University	Undergraduate Degree
Kellogg School of Management	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di John Ruesch

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ASTRIA THERAPEUTICS, INC.	Health Technology

Aziende private	1
Surface Oncology, Inc. Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.	Health Technology